:: ±Û´äº¯ ::
ÀÌ ¸§
ÆÐ½º¿öµå
À̸ÞÀÏ
ȨÆäÀÌÁö
¿É ¼Ç
html
Á¦ ¸ñ
> > > ÓßúÉÒýÑûàõì»å룬ð¯ìéóÜ×éÄ KAMAGRA-100 â©ÍýÚ«Ï¢ùßø¸ èÙèÙ既Ñ¢ÓâéÑÑÌíå¡£îÏγìÔÓøð²ðãîÜ íàåÕå·£¨Sildenafil 100mg£© ì¤Ðì Ï¢ùß即ûù¡¢öááÜýå⥡¢Òýðúâ©ÍýÏ¢Ú« ûú øµåÚ攜Óá îÜ÷åàõ£¬î¤ãæâ¢ÑûàõñéÞªßÈáôü¶çÊ¡£ïáü¬îÜÞÅéÄÛ°ÛöÜôÐÁç¯úÂå·üù£¬ü½Î¼ÌõÓðäÌîïæ¨ÜùíÂéÄÍó𤡣ÜâÙþíâÌ¿ùê îöÊ«Ëïì¡¡¢×üßÉâ¦Ëàì¤ÐàÞÅéÄíºüÞÏú£¬ð«Íêð¯ìéóÞÅéÄ KAMAGRA-100 îÜèÇïÚãæâ¢教ùÊ¡£ > > 3330.jpg > > ìé¡¢Öõú° KAMAGRA-100 Ï¢ùßø¸îÜå·×â÷åàõ > KAMAGRA-100 â©ÍýÚ«Ï¢ùßø¸ ãÀìéðú PDE5 åäð¤ð¥£¬üÀàõà÷ÝÂ為 à¤ò¢ÑáÞª£¨Sildenafil£©¡£Ðìñ«é©íÂéÄѦð¤åýù»£º > > åäð¤ PDE5 酶üÀàõ > > PDE5 ãÀëäÌìúØúô÷Ò®ÝÂú° cGMP îÜμËõ酶¡£ > > à¤ò¢Ñáުʦåäð¤ PDE5£¬ÞÅ cGMP â©øÁã®ÍÔ£¬õµòäøÁüÁÑ¿à¢í壬ñòÊ¥úì×µ£¬Ó¹ÓðÚúÑÃüùÍý¡£ > > Ï¢ùßýåâ¥öá > > å·Úª÷âΦϢ˷黏دòÁïÈòäìýúìäû£¬ùØóÝ»ÝÂâÏÔ¤ÓÛÞó£¨First-pass metabolism£©£¬Ýïîî÷ÖÏ¢Ü×ïüÑÃüùÌÚöá¡£ > > ×üßÉãËúÐúéãÆÏ¢ùßø¸ÑÃüùøÁгãÁÊà å³ 15–30 ÝÂñ¤£¨ÕÎê¹£ºInternational Journal of Impotence Research, 2018£©¡£ > > å·üùò¥áÙãÁÊà > > KAMAGRA-100 îÜå·üùʦò¥áÙ 4–6 á³ãÁ£¬Ý»ÝÂÞÅéÄíºÊ¦Ó¹ 8 á³ãÁ£¬æ¨àõí©ÌÔÒãÁíÂéÄ¡£ > > îÏÞÁå·×âò±ãÛÓß ð¯ìéóÞÅéÄ KAMAGRA-100 îÜãæâ¢ ÞªßÈñìé©£¬Ê¦幫ð¾×âú°為ä§麼 ÍöÜÙÜ×éÄÑÃüùÌÚöᣬì¤Ðà為ù¼àõí©Ìù±âÎðíî¤î¦ÒöÓ¹ÓðÚúÑÃüùÍý¡£ > > > > 죡¢âÏóÞÅéÄ KAMAGRA-100 îñîÜñÞÝá > ð¯ìéóÞÅéÄ KAMAGRA-100 îñ£¬Ëïì¡ñ¼ëòì¤ù»ÞÀú££º > > í¿âóì¢ÞÔ > > ü¬ìãí»ãóÙÒêó åññìãýúìηòðÜ»¡¢î¸úìäâûäÍÔúìä⣬ûäïáî¤Ü×éÄ õ¦ß«ç¤×¾å·Úª¡£ > > 研ϼúéãÆ£¬ãýúìηü´íºî¤Ú±í¿âóì¢ÞÔîÜï×üÏù»ÞÅéÄ PDE5 åäð¤ð¥£¬Ê¦ÒöñòÊ¥ãýÑ¿ÌÀúìù¦úÏ£¨ÕÎê¹£ºAmerican Heart Association, 2020£©¡£ > > àÔ÷ÉÍöÜÙûäÌîãÝßÒ÷¾ > > ÍÔò·óÉüåæÅòÀå·Úªýå⥠60–120 ÝÂñ¤£¬Ë½î¸úìå·ÒØÓø 20–30%£¨ÕÎê¹£ºJournal of Sexual Medicine, 2016£©¡£ > > ÍöÜÙÜ×éÄÒöð«ÍÔúìñéà¤ò¢ÑáÞªÒØÓø£¬ð«ã®ÚúÑÃÌãÓøûúò¥áÙãÁÊà¡£ > > ñÞÝáá´Õáâ© > > âÌæÔÏ¢ùßø¸Ê¦òÁïÈýå⥣¬Ó£Ï¢ËëãÁá´Õáâ©êóð¾åÚå·ø¸éÁú°¡£ > > ÜÁò¥à¢îê¡¢Û¯鬆îÜü»ÌÑ > > ãý×âßÒ÷¾æ¨àõí©Ìüåç¯úÂå·üù£¬Û¯鬆ãýï×ʦð«ÍÔ KAMAGRA-100 îÜêóüùàõ¡£ > > 3333.png > > ß²¡¢âÏóÜ×éÄ KAMAGRA-100 îÜÜÆö® > ÑÃã·ð¥Õá > > Ëïì¡ãæâ¢ðô 50mg ËÒã·£¨65 á¨ì¤ß¾Ñûàõʦðô 25mg ËÒã·£©¡£ > > å´üùÍýÜôð룬ʦðàïÚò¸ 100mg£¬Ó£ØßìíÜôʦõ±Î¦ 100mg¡£ > > Ü×éÄÛ°Ûö > > íâÏ¢ùßø¸Û¯ìýÏ¢ñéí»æÔéÁú°£¬ùØóîºíÄûäòÁïÈ吞ù»¡£ > > ÑÃüùøÁг 15–30 ÝÂñ¤£¬å·üùʦò¥áÙ 4–6 á³ãÁ£¬Ý»ÝÂÞÅéÄíºÊ¦Ó¹ 8 á³ãÁ¡£ > > àõí©Ìù±âÎðíî¤ > > PDE5 åäð¤ð¥ÐÁî¤àõí©Ìù»Û¡ýÆíÂéÄ£¬Ó¤âíÜ×éÄÙíÛöí»ÔÑÚúÑᣠ> > κóÌÜùíÂéÄ > > ßÈ̸ÌîÚ°ÜùíÂéÄøÐÎÀ£ºÔéý»¡¢臉ûõ¡¢Þ¬ßÝ¡¢ÌîÚ°Ôé÷Ô¡£ > > å´õóúÞýØÚ¿¡¢Ð¼ÖÔé÷ÔûäãÊÕôì¶ßÈ£¬ëëØ¡即ïÎå·並ö¦ì¢¡£ > > Ú¸ÏÐ FDA Ëïì¡£¬õóúÞåññìÜùíÂéÄãÁ£¬ëëØ¡即ÚüöèÐáÏï³ü¥ûäîñèÙÐáòࣨÕÎê¹£ºFDA Drug Safety Communication, 2019£©¡£ > > 33.png > > ÞÌ¡¢ÍöÜÙæ¨ÚùýÜ×éÄ KAMAGRA-100 îÜó¬ì¶ > ÍöÜÙÜ×éÄ > > ÑÃüùõÌöᣬúìñéà¤ò¢ÑáÞªÒØÓøÓ¹ÜèãÁÊàõÌÓ¡£ > > ×üßÉâ¦ËàúéãÆ£¬ÍöÜÙÜ×éÄʦÞÅøÁгÑÃüùãÁÊàõêÓå³ 20 ÝÂñ¤£¨ÕÎê¹£ºInternational Journal of Clinical Pharmacology, 2017£©¡£ > > ÌîãÝýÜ×éÄ > > êÖÚÂÊïíºÊ¦àÔ÷É£¬Ó£ÑÃüùõªØ·£¬úìñéÒØÓøÕÔ£ > > ÍÔò·óÉýÜ×éÄ > > ÑÃüùæÅòÀ 60–120 ÝÂñ¤£¬å·üù˽£ > > îöÊ«Ëïì¡ãæâ¢õÌû¿àÔ÷É ÍöÜÙûäÌîãÝý 1–2 á³ãÁ Ü×éÄ£¬ì¤üòÔðõÌÊ¢ KAMAGRA-100 ÑÃüùüùÍý¡£ > > 23232323.png > > çé¡¢KAMAGRA-100äÌîïÞÅéÄæ¨ñ¼ëòÞÀú£ > ùØóæ¨õ¦ß«ç¤×¾å·ÚªÔÒãÁÞÅéÄ > > ʦÒöÓôöÈúìäâÐá˽£¬ñòÊ¥ãýúìηù¦úÏ¡£ > > ùØóÍÔò·óÉæ¨Î¦ÕáñÐïñ > > ʦ˽î¸úìñéÒØÓø£¬ç¯úÂÚúÑÃÌãÓø¡£ > > ñåáúð¥ÕáЮÛô > > ØßìíÜôʦõ±Î¦ 100mg£¬ùØóñòÊ¥ÜùíÂéÄù¦úÏ¡£ > > ׺ëòËÁìÑô÷òõÚãëë > > å´õóúÞÔéý»¡¢ãÊÕôì¶ßÈ¡¢ýØÚ¿ÔõñøßÒ£¬Ø¡即ïÎå·並ö¦ì¢¡£ > > ׿¡¢Ì¿Ö壺ãæâ¢ÞÅéÄ KAMAGRA-100 îÜüÜÑÑóþÕÔ > ð¯ìéóÞÅéÄ KAMAGRA-100 â©ÍýÚ«Ï¢ùßø¸ îÜÑûàõ£¬Ê¦ñåâàì¤ù»óþÕÔ£º > > à»í¿âóì¢ÞÔü¬ìãäÌîï¡£ > > àÔ÷É ÍöÜÙûäÌîãÝý 1–2 á³ãÁ Ü×éÄ¡£ > > ÑÃã·ð¥Õá 50mg£¬ù±é©ãÁðàïÚò¸ 100mg¡£ > > Ï¢ùßø¸Û¯ìýÏ¢ñéí»æÔéÁú°£¬ÔõÓâ 15–30 ÝÂñ¤ ÑÃüù¡£ > > àõí©Ìù±âÎðí¬並κóÌÜùíÂéÄ¡£ > > íæäÄì¤ß¾Û°Ûö£¬ãæâ¢å¥Òö äÌîï¡¢êóüùò¢ÞÅéÄ KAMAGRA-100£¬ð«ã®ÚúÑÃÌãÓøæ¨ò¥ÎùÓø£¬ñìã¦àõßæüÀãáãý¡£ > > ßÓμ產ù¡õÏôÀ£ºìÔÓøâíòäÏ¢ïáù¡ù±××ÌÍPriligy(POXET-60) ClimaxìÔÓøãêêú Ú¸ÏÐüÜÑÑêÉʨViagra ìÔÓøäªüùäÅêÎíࣨLevifil£© Ú¸ÏС¼MMC¡½MAXMAN äû÷¾ÍýÔÐêÎì»Ë¼MALEGRA ýÙâ©Ð¡ Extra Super Filanað¯ÞÌÓÛAvanafilõ±ÐäêÎì»Ë¼äªüù ÌÚÒý產ù¡ßÙï×òäìýˬäÅå·ÏÑwww.kl19.tw 24á³ãÁËÔÜ×line:kl198888 > > æÅãßæóÔÁ£ºKAMAGRA-100 ïáü¬ÞÅéÄÛ°Ûöæ¨ð¥Õáò¦Ñõ >
¸µÅ© #1
¸µÅ© #2
ÆÄÀÏ÷ºÎ
¿ÞÂÊÀÇ ±ÛÀÚ¸¦ ÀÔ·ÂÇϼ¼¿ä.